1 Study Matches
PSCI 21-038 Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK-rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
Clinical trial on the treatment of persons who are diagnosed with Lung Cancer.
18 year(s) or older
Inclusion Criteria:lung cancer
Exclusion Criteria:other cancer in the last 3 years
major surgery in the last 30 days
heart attack or stroke in the last 6 months